ReviewFrontiers in endocrinology2021
Safety of Pediatric rhGH Therapy: An Overview and the Need for Long-Term Surveillance.
Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chinese herbal medicine for children with idiopathic short stature (ISS): A systematic review and meta-analysis.PloS one · 2022Pooled it
- Clinical consensus guidelines for the management of Noonan syndrome in Japan.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026Article
- Exploratory secondary analysis of published aggregate growth and metabolic data in children born small for gestational age treated with growth hormone.Frontiers in endocrinology · 2026Review
- A real-world investigation of drug-induced hyperglycemia and diabetes mellitus in pediatric populations using the FDA adverse event reporting system.Frontiers in medicine · 2026Article
- Capsaicin diet drives gut inflammation and exosomal miR-17-3p elevation in idiopathic short stature.Nature communications · 2025Article
- Noonan Syndrome, Cancer Risk, and Growth Hormone TreatmentJournal of clinical research in pediatric endocrinology · 2025Review
- Nutritional Counseling in Children with Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone: Analysis of Growth Response Parameters.Biomedicines · 2025Article
- Calcium Supplement Combined with Dietary Supplement Kidtal Can Promote Longitudinal Growth of Long Bone in Calcium-Deficient Adolescent Rats.Nutrients · 2025Article
- Meclozine and growth hormone ameliorate bone length and quality in experimental models of achondroplasia.Journal of bone and mineral metabolism · 2025Article
- To Evaluate the Effect of Pediatric Massage Combined with Comprehensive Management on Growth Parameters and Biochemical Indicators in Children with Short Stature.International journal of general medicine · 2025Article
- Development of a Minimum Dataset for the Monitoring of Recombinant Human Growth Hormone Therapy in Children with Growth Hormone Deficiency: A GloBE-Reg Initiative.Hormone research in paediatrics · 2024Article
- Real-life long-term efficacy and safety of recombinant human growth hormone therapy in children with short stature homeobox-containing deficiency.Endocrine connections · 2023Article
- Glucocorticoid induced bone disorders in children: Research progress in treatment mechanisms.Frontiers in endocrinology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth hormone (GH) therapy dates back to 1958 and, though has shown an excellent safety profile in the short-term, has never ceased to raise concern about potential long-term side effects. In the last decade, a number of observational studies in different cohorts of young adult patients treated with GH during childhood have yielded conflicting results. The attention has mainly focused on three major potential risks associated with GH therapy: cancer, cardio and cerebrovascular diseases and diabetes. This review intends to provide a detailed overview of the main studies reporting long-term safety in subjects treated with rhGH therapy during childhood, highlighting the evidence for or against the risk of cancer, cardio and cerebrovascular diseases and diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.